Chairat Shayakul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chairat Shayakul has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Charanya Nawarat
Renal Division, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
2 shared publications - Naparat Kaewkaukul
Renal Division, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
2 shared publications Alan K Stuart-Tilley
1 shared publicationAmphorn Sorthananusak
Galyani Vadhana Hemodialysis Unit, Siriraj Hospital, Bangkok, Thailand
1 shared publicationBusaya Kulabusaya
Pharmacy Department, Siriraj Hospital, Bangkok, Thailand
1 shared publicationChristlieb Haller
1 shared publication
Latest Publications
- Open Access
Long-Term Kidney Outcomes in COVID-19 Survivors with and Without Acute Kidney Injury
Background and Objectives: Acute kidney injury (AKI) is a common complication of COVID-19 and is associated with increased short-term mortality. However, long-term kidney outcomes among survivors remain incompletely characterized. Materials and Methods: We conducted a cohort study of hospitalized COVID-19 patients at a tertiary care university hospital, classifying them during admission according to the KDIGO AKI criteria. Survivors underwent follow-up assessment approximately 1.5–2 years post-discharge, which included laboratory evaluations and a structured questionnaire. This questionnaire collected patient-reported outcomes regarding post-discharge health worsening and any new medical diagnoses during the follow-up period. The primary outcome was kidney function decline (eGFR 2 together with a ≥25% decrease from discharge) among survivors with follow-up eGFR; all-cause mortality was analyzed separately. Associated factors were identified using modified Poisson regression models. Results: A total of 180 patients were included (60 with AKI and 120 without); kidney outcomes were analyzed in 100 patients with follow-up eGFR (44 and 56 respectively). Patients with AKI were older, had more comorbidities, and experienced more severe COVID-19. At a median follow-up of 1.65 years, 4 of 60 patients with AKI had died and one required kidney transplantation. Among the 100 analyzed patients, patient-reported worsening of overall health and newly diagnosed conditions did not differ significantly between groups. Kidney function decline occurred in 23 of 44 patients with AKI (52.3%) and 3 of 56 patients without AKI (5.4%); the AKI group also had lower follow-up eGFR and greater eGFR decline. In multivariable analysis, AKI remained independently associated with the primary outcome (adjusted RR 7.92, 95% CI 2.41–25.98; p < 0.001). Conclusions: Among COVID-19 survivors, AKI is associated with long-term kidney function decline and higher mortality. These findings support the need for structured post-discharge kidney monitoring in this high-risk population.
Open AccessLong-Term Kidney Outcomes in COVID-19 Survivors with and Without Acute Kidney Injury
Background and Objectives: Acute kidney injury (AKI) is a common complication of COVID-19 and is associated with increased short-term mortality. However, long-term kidney outcomes among survivors remain incompletely characterized. Materials and Methods: We conducted a cohort study of hospitalized COVID-19 patients at a tertiary care university hospital, classifying them during admission according to the KDIGO AKI criteria. Survivors underwent follow-up assessment approximately 1.5–2 years post-discharge, which included laboratory evaluations and a structured questionnaire. This questionnaire collected patient-reported outcomes regarding post-discharge health worsening and any new medical diagnoses during the follow-up period. The primary outcome was kidney function decline (eGFR 2 together with a ≥25% decrease from discharge) among survivors with follow-up eGFR; all-cause mortality was analyzed separately. Associated factors were identified using modified Poisson regression models. Results: A total of 180 patients were included (60 with AKI and 120 without); kidney outcomes were analyzed in 100 patients with follow-up eGFR (44 and 56 respectively). Patients with AKI were older, had more comorbidities, and experienced more severe COVID-19. At a median follow-up of 1.65 years, 4 of 60 patients with AKI had died and one required kidney transplantation. Among the 100 analyzed patients, patient-reported worsening of overall health and newly diagnosed conditions did not differ significantly between groups. Kidney function decline occurred in 23 of 44 patients with AKI (52.3%) and 3 of 56 patients without AKI (5.4%); the AKI group also had lower follow-up eGFR and greater eGFR decline. In multivariable analysis, AKI remained independently associated with the primary outcome (adjusted RR 7.92, 95% CI 2.41–25.98; p < 0.001). Conclusions: Among COVID-19 survivors, AKI is associated with long-term kidney function decline and higher mortality. These findings support the need for structured post-discharge kidney monitoring in this high-risk population.
- Open Access
- 6 October 2026
- Published by MDPI AG in Preprints.org
Long-Term Kidney Outcomes in COVID-19 Survivors With and Without Acute Kidney Injury
Background and Objectives: Acute kidney injury (AKI) is a common complication of COVID-19 and is associated with increased short-term mortality. However, long-term kidney outcomes among survivors remain incompletely characterized. Materials and Methods: We conducted a cohort study of hospitalized COVID-19 patients at a tertiary care university hospital, classifying them during admission according to the KDIGO AKI criteria. Survivors underwent follow-up assessment approximately 1.5–2 years post-discharge, which included laboratory evaluations and a structured questionnaire. This questionnaire collected patient-reported outcomes regarding post-discharge health worsening and any new medical diagnoses during the follow-up period. The primary outcome was a composite of all-cause mortality or kidney function decline (defined as an eGFR < 60 mL/min/1.73 m² and a ≥25% decrease from discharge). Associated factors were identified using modified Poisson regression models. Results: A total of 180 patients were included (60 with AKI and 120 without). Patients with AKI were older, had more comorbidities, and experienced more severe COVID-19. At a median follow-up of 1.65 years, 4 patients with AKI had died and one required kidney transplantation. Patients in AKI group more frequently reported worsening overall health and newly diagnosed conditions (both p < 0.05). The composite outcome occurred more frequently in the AKI group including lower follow-up eGFR and greater eGFR decline. In multivariable analysis, AKI remained independently associated with the primary outcome (adjusted RR 7.92, 95% CI 2.41–25.98; p < 0.001). Conclusions: Among COVID-19 survivors, AKI is associated with worsening patient-reported health status and adverse long-term outcomes, including kidney function decline and death. These findings support the need for structured post-discharge kidney monitoring in this high-risk population.
- 6 October 2026
- Published by MDPI AG in Preprints.org
Open AccessLong-Term Kidney Outcomes in COVID-19 Survivors With and Without Acute Kidney Injury
Background and Objectives: Acute kidney injury (AKI) is a common complication of COVID-19 and is associated with increased short-term mortality. However, long-term kidney outcomes among survivors remain incompletely characterized. Materials and Methods: We conducted a cohort study of hospitalized COVID-19 patients at a tertiary care university hospital, classifying them during admission according to the KDIGO AKI criteria. Survivors underwent follow-up assessment approximately 1.5–2 years post-discharge, which included laboratory evaluations and a structured questionnaire. This questionnaire collected patient-reported outcomes regarding post-discharge health worsening and any new medical diagnoses during the follow-up period. The primary outcome was a composite of all-cause mortality or kidney function decline (defined as an eGFR < 60 mL/min/1.73 m² and a ≥25% decrease from discharge). Associated factors were identified using modified Poisson regression models. Results: A total of 180 patients were included (60 with AKI and 120 without). Patients with AKI were older, had more comorbidities, and experienced more severe COVID-19. At a median follow-up of 1.65 years, 4 patients with AKI had died and one required kidney transplantation. Patients in AKI group more frequently reported worsening overall health and newly diagnosed conditions (both p < 0.05). The composite outcome occurred more frequently in the AKI group including lower follow-up eGFR and greater eGFR decline. In multivariable analysis, AKI remained independently associated with the primary outcome (adjusted RR 7.92, 95% CI 2.41–25.98; p < 0.001). Conclusions: Among COVID-19 survivors, AKI is associated with worsening patient-reported health status and adverse long-term outcomes, including kidney function decline and death. These findings support the need for structured post-discharge kidney monitoring in this high-risk population.
- Open Access
- 1 February 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 467-477
Medication Adherence, Complementary Medicine Usage and Progression of Diabetic Chronic Kidney Disease in Thais
Purpose: Non-adherence to medication is receiving more attention as a significant problem common to management of chronic diseases including diabetes and chronic kidney disease (CKD). This study was designed to assess the medication adherence and self-medication in a cohort of Thai patients with diabetic kidney disease, and its association with clinical outcomes. Patients and Methods: Non-dialysis patients with diabetic CKD visiting outpatient’s clinics of Siriraj Hospital, the largest tertiary care in Thailand, were asked for participation. Self-administered questionnaire was given to assess medication adherence (the 6-item-medication-taking-behavior measure in Thai), complementary medicine usage, and personal information. Clinical, pharmaceutical, and relevant laboratory data (at current and the last visit of around 12 months) were abstracted from the medical records. Results: Of the 220 participants eligible (54.1% male, mean age 71.3), 50.9%, 24.1%, and 25% were classified as high-, medium-, and low-medication adherence, respectively. Overall, 24.1% reported self-usage of at least one type of herbal or complementary medicines. The most commonly identified items were cordyceps, cod liver oil, Nan Fui Chao, and turmeric (6 each), with unidentified Thai herbal mixture in 11. On multivariate analysis, late-stage CKD (stage IV–V) was the only independent predictor for low adherence (odds ratio (OR), 5.54; 95% confidence interval (CI), 2.82– 10.88). Low adherence was associated with higher blood pressure, lower estimated glomerular filtrate rate (eGFR), and more eGFR decline with greater risk of being rapid CKD progressor (annual eGFR drop > 5 mL/min/1.73 m2) [OR, 1.15; 95% CI, 1.06– 1.25]. Conclusion: Medication taking behavior was a frequently encountered problem in Thai diabetic CKD patients. Increased medication non-adherence was independently predicted by stages of increasing CKD severity, and it was associated with poorer hypertensive control and kidney outcome. Targeting interventions to improve medication adherence should be an important strategy to slow CKD progression among patients with diabetic CKD.
- 1 February 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 467-477
Open AccessMedication Adherence, Complementary Medicine Usage and Progression of Diabetic Chronic Kidney Disease in Thais
Purpose: Non-adherence to medication is receiving more attention as a significant problem common to management of chronic diseases including diabetes and chronic kidney disease (CKD). This study was designed to assess the medication adherence and self-medication in a cohort of Thai patients with diabetic kidney disease, and its association with clinical outcomes. Patients and Methods: Non-dialysis patients with diabetic CKD visiting outpatient’s clinics of Siriraj Hospital, the largest tertiary care in Thailand, were asked for participation. Self-administered questionnaire was given to assess medication adherence (the 6-item-medication-taking-behavior measure in Thai), complementary medicine usage, and personal information. Clinical, pharmaceutical, and relevant laboratory data (at current and the last visit of around 12 months) were abstracted from the medical records. Results: Of the 220 participants eligible (54.1% male, mean age 71.3), 50.9%, 24.1%, and 25% were classified as high-, medium-, and low-medication adherence, respectively. Overall, 24.1% reported self-usage of at least one type of herbal or complementary medicines. The most commonly identified items were cordyceps, cod liver oil, Nan Fui Chao, and turmeric (6 each), with unidentified Thai herbal mixture in 11. On multivariate analysis, late-stage CKD (stage IV–V) was the only independent predictor for low adherence (odds ratio (OR), 5.54; 95% confidence interval (CI), 2.82– 10.88). Low adherence was associated with higher blood pressure, lower estimated glomerular filtrate rate (eGFR), and more eGFR decline with greater risk of being rapid CKD progressor (annual eGFR drop > 5 mL/min/1.73 m2) [OR, 1.15; 95% CI, 1.06– 1.25]. Conclusion: Medication taking behavior was a frequently encountered problem in Thai diabetic CKD patients. Increased medication non-adherence was independently predicted by stages of increasing CKD severity, and it was associated with poorer hypertensive control and kidney outcome. Targeting interventions to improve medication adherence should be an important strategy to slow CKD progression among patients with diabetic CKD.
- 31 January 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1414-1418
Optimal Time for Recirculation with Ultrafiltration to Remove Disinfectant in Reused Dialyzer
The practice of dialyzer reuse is common in developing countries. One essential technique for safe dialyzer reprocessing is to remove disinfectants properly to the recommended standards before treatment initiation, using dialysis machine recirculation with ultrafiltration. This study was conducted to identify the most effective time for carrying out this procedure, and the factors affecting it. We studied 420 high-flux dialyzers with three different membrane types: FB210U (cellulose triacetate), F80S (polysulfone), and Elisio-210HR (polyethersulfone) at four reused cycles (5th, 10th, 15th, and 19th). Peracetic acid was used as the disinfectant at a concentration of 0.16%. The total cell volume (TCV) and clot inspection grade of the reused dialyzer were recorded before the procedure. The optimal time for disinfectant removal was independently determined by two observers using the residual peroxide strip test of the ultrafiltrate. We observed that disinfectant removal was dependent on the recirculation time and became undetectable at 5 minutes. The type of dialyzer had a significant effect on the effective recirculation time (shortest for FB210U followed by Elisio-210HR and F80S; p < 0.001), but the reused number, TCV, and clot inspection grade did not. It is conceivable that the dialyzer membrane type might affect peracetic acid removal. In conclusion, the interval for carrying out dialysis machine recirculation with ultrafiltration depends on the dialyzer type, and 5 minutes is the optimal time for the operation. This result can be implemented to improve further practice in dialyzer reprocessing.
- 31 January 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1414-1418
Optimal Time for Recirculation with Ultrafiltration to Remove Disinfectant in Reused Dialyzer
The practice of dialyzer reuse is common in developing countries. One essential technique for safe dialyzer reprocessing is to remove disinfectants properly to the recommended standards before treatment initiation, using dialysis machine recirculation with ultrafiltration. This study was conducted to identify the most effective time for carrying out this procedure, and the factors affecting it. We studied 420 high-flux dialyzers with three different membrane types: FB210U (cellulose triacetate), F80S (polysulfone), and Elisio-210HR (polyethersulfone) at four reused cycles (5th, 10th, 15th, and 19th). Peracetic acid was used as the disinfectant at a concentration of 0.16%. The total cell volume (TCV) and clot inspection grade of the reused dialyzer were recorded before the procedure. The optimal time for disinfectant removal was independently determined by two observers using the residual peroxide strip test of the ultrafiltrate. We observed that disinfectant removal was dependent on the recirculation time and became undetectable at 5 minutes. The type of dialyzer had a significant effect on the effective recirculation time (shortest for FB210U followed by Elisio-210HR and F80S; p < 0.001), but the reused number, TCV, and clot inspection grade did not. It is conceivable that the dialyzer membrane type might affect peracetic acid removal. In conclusion, the interval for carrying out dialysis machine recirculation with ultrafiltration depends on the dialyzer type, and 5 minutes is the optimal time for the operation. This result can be implemented to improve further practice in dialyzer reprocessing.
- 1 February 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (2) , 371-379
Characterization of a highly polymorphic marker adjacent to the SLC4A1 gene and of kidney immunostaining in a family with distal renal tubular acidosis
Mutations in the human SLC4A1 (AE1/band 3) gene are associated with hereditary spherocytic anaemia and with distal renal tubular acidosis (dRTA). The molecular diagnosis of AE1 mutations has been complicated by the absence of highly polymorphic genetic markers, and the pathogenic mechanisms of some dRTA-associated AE1 mutations remain unclear. Here, we characterized a polymorphic dinucleotide repeat close to the human AE1 gene and performed an immunocytochemical study of kidney tissue from a patient with inherited dRTA with a defined AE1 mutation. One CA repeat region was identified in a phage P1-derived artificial chromosome (PAC) clone containing most of the human AE1 gene and the upstream flanking region. We determined its heterozygosity value in multiple populations by PCR analysis. Genotyping of one family with dominant dRTA identified the AE1 R589H mutation, and family member genotypes were compared with the CA repeat length. AE1 and vH(+)-ATPase polypeptides in kidney tissue from an AE1 R589H patient were examined by immunocytochemistry for the first time. This CA repeat, previously reported as D17S1183, is approximately 90 kb upstream of the AE1 gene and displayed considerable length polymorphism, with small racial differences, and a heterozygosity value of 0.56. The allele-specific length of this repeat confirmed co-segregation of the AE1 R589H mutation with the disease phenotype in a family with dominant dRTA. Immunostaining of the kidney cortex from one affected member with superimposed chronic pyelonephritis revealed vH(+)-ATPase-positive intercalated cells in which AE1 was undetectable, and proximal tubular epithelial cells with apparently enhanced apical vH(+)-ATPase staining. The highly polymorphic dinucleotide repeat adjacent to the human AE1 gene may be useful for future studies of disease association and haplotype analysis. Intercalated cells persist in the end-stage kidney of a patient with familial autosomal dominant dRTA associated with the AE1 R589H mutation. The absence of detectable AE1 polypeptide in those intercalated cells supports the genetic prediction that the AE1 R589H mutation indeed causes dominant dRTA.
- 1 February 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (2) , 371-379
Characterization of a highly polymorphic marker adjacent to the SLC4A1 gene and of kidney immunostaining in a family with distal renal tubular acidosis
Mutations in the human SLC4A1 (AE1/band 3) gene are associated with hereditary spherocytic anaemia and with distal renal tubular acidosis (dRTA). The molecular diagnosis of AE1 mutations has been complicated by the absence of highly polymorphic genetic markers, and the pathogenic mechanisms of some dRTA-associated AE1 mutations remain unclear. Here, we characterized a polymorphic dinucleotide repeat close to the human AE1 gene and performed an immunocytochemical study of kidney tissue from a patient with inherited dRTA with a defined AE1 mutation. One CA repeat region was identified in a phage P1-derived artificial chromosome (PAC) clone containing most of the human AE1 gene and the upstream flanking region. We determined its heterozygosity value in multiple populations by PCR analysis. Genotyping of one family with dominant dRTA identified the AE1 R589H mutation, and family member genotypes were compared with the CA repeat length. AE1 and vH(+)-ATPase polypeptides in kidney tissue from an AE1 R589H patient were examined by immunocytochemistry for the first time. This CA repeat, previously reported as D17S1183, is approximately 90 kb upstream of the AE1 gene and displayed considerable length polymorphism, with small racial differences, and a heterozygosity value of 0.56. The allele-specific length of this repeat confirmed co-segregation of the AE1 R589H mutation with the disease phenotype in a family with dominant dRTA. Immunostaining of the kidney cortex from one affected member with superimposed chronic pyelonephritis revealed vH(+)-ATPase-positive intercalated cells in which AE1 was undetectable, and proximal tubular epithelial cells with apparently enhanced apical vH(+)-ATPase staining. The highly polymorphic dinucleotide repeat adjacent to the human AE1 gene may be useful for future studies of disease association and haplotype analysis. Intercalated cells persist in the end-stage kidney of a patient with familial autosomal dominant dRTA associated with the AE1 R589H mutation. The absence of detectable AE1 polypeptide in those intercalated cells supports the genetic prediction that the AE1 R589H mutation indeed causes dominant dRTA.